Evidence of Reporting Biases in Voxel-Based Morphometry (VBM) Studies of Psychiatric and Neurological Disorders

Paolo Fusar-Poli,^{1,2}* Joaquim Radua,^{1,3} Marianna Frascarelli,^{1,4} Andrea Mechelli,¹ Stefan Borgwardt,⁵ Fabio Di Fabio,⁴ Massimo Biondi,⁴ John P.A. Ioannidis,^{6,7,8} and Sean P. David^{9,10}

¹Department of Psychosis Studies, Institute of Psychiatry, King's College London, United Kingdom ²OASIS team, South London and the Maudsley NHS Foundation Trust, London, United Kingdom ³FIDMAG Germanes Hospitalaries, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain ⁴Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy ⁵Department of Psychiatry, University of Basel, Basel, Switzerland ⁶Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California ⁷Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California ⁸Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, California ⁹Division of General Medical Disciplines, Department of Medicine, Stanford University School of Medicine, Stanford, California ¹⁰SRI International, Center for Health Sciences, Biosciences Division, Menlo Park, California

Abstract: *Objectives:* To evaluate whether biases may influence the findings of whole-brain structural imaging literature. *Methods:* Forty-seven whole-brain voxel-based meta-analyses including voxel-based morphometry (VBM) studies in neuropsychiatric conditions were included, for a total of 324 individual VBM studies. The total sample size, the overall number of foci, and different moderators were extracted both at the level of the individual studies and at the level of the meta-analyses. *Results:* Sample size ranged from 12 to 545 (median n = 47) per VBM study. The median number of reported foci per study was six. VBM studies with larger sample sizes reported only slightly more abnormalities than smaller studies (2% increase in the number of foci per 10-patients increase in sample size). A similar pattern was seen in several analyses according to different moderator variables with some possible modulating evidence for the statistical threshold employed, publication year and number of coauthors.

*Correspondence to: Dr. Paolo Fusar-Poli, Department of Psychosis Studies, Institute of Psychiatry PO63, De Crespigny Park, London SE58AF, United Kingdom. E-mail: paolo.fusar-poli@kcl.ac.uk Received for publication 2 March 2013; Revised 19 June 2013; Accepted 23 July 2013.

DOI 10.1002/hbm.22384 Published online 7 October 2013 in Wiley Online Library (wileyonlinelibrary.com).

© 2013 The Authors. Human Brain Mapping published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Additional Supporting Information may be found in the online version of this article.

Whole-brain meta-analyses (median sample size n = 534) found fewer foci (median = 3) than single studies and overall they showed no significant increase in the number of foci with increasing sample size. Meta-analyses with ≥ 10 VBM studies reported a median of three foci and showed a significant increase with increasing sample size, while there was no relationship between sample size and number of foci (median = 5) in meta-analyses with <10 VBM studies. *Conclusions:* The number of foci reported in small VBM studies and even in meta-analyses with few studies may often be inflated. This picture is consistent with reporting biases affecting small studies. *Hum Brain Mapp* 35:3052–3065, 2014. © 2013 Wiley **Periodicals, Inc.**

Key words: neuroimaging; VBM; structural; bias; psychosis; dementia

INTRODUCTION

Structural magnetic resonance imaging (sMRI) studies have been carried out by many researchers in different neuropsychiatric conditions including psychosis, depression, dementia, attention deficit hyperactivity disorder (ADHD) and autistic disorders. Often, the morphometric measurements used in these studies have been obtained from a priori regions of interests (ROIs) that can be clearly defined (such as the hippocampi or the ventricles) [Ashburner and Friston, 2000]. However, there are a number of morphometric features that may be more difficult to quantify by inspection, meaning that many structural differences may be over or under looked. The caveat of the ROIs structural analyses is that, because of these difficulties, researchers can introduce a large source of heterogeneity undermining the consistency of their results. These problems may ultimately prevent clinical application of sMRI to psychiatry [Borgwardt and Fusar-Poli, 2012]. To address this limitation, an advanced structural imaging technique has been recently introduced and widely applied. Voxelbased morphometry (VBM) involves a voxel-wise comparison of the local concentration of gray matter between two or more groups of subjects. The procedure usually involves spatially normalizing high-resolution images from all the subjects in the study into the same stereotactic space, segmenting the gray and white matter and smoothing the resulting gray-matter segments. Some protocols also include a 'modulation' step, but its effects are disputed (Radua et al. 2013). Voxel-wise parametric or non-parametric statistical tests comparing the experimental groups are then performed correcting for multiple comparisons. The value of this automated analytical approach is that it gives an "even-handed and comprehensive assessment of anatomical differences throughout the brain" without necessarily biasing attention a priori to a specific ROI [Laird et al., 2005]. Because of this, VBM is considered an objective method to analyze whole-brain structural abnormalities in neuroscience and psychiatric research and bridge structural neuroimaging toward clinical applications. However, it is unclear whether the current VBM literature can still be affected by biases, in particular publication and other selective reporting biases, where

investigators selectively report statistically significant results and under-report non-significant findings – as noted for sMRI studies [Ioannidis, 2011].

Detecting these biases in single studies is difficult: by default it is very difficult to unearth unpublished studies and unless the original protocol is available it is not possible to check whether the presented results are more favorable (e.g., claim more discovered foci with abnormalities) than an analysis based on the original protocol. However, one may obtain hints about the presence of such biases, when many studies have been performed. In the absence of bias, one would expect power to detect abnormalities to improve when sample size increases, other things being equal. Conversely, with such biases small studies with unimpressive null results may be unpublished, or they may be analyzed in a way that they provide more foci. Evidence from many different scientific fields suggests that bias may affect to a lesser extent large studies, since these are likely to be published regardless of their results and analytical manipulation may be less prominent [Rothstein HR et al., 2005].

The first aim of this study was to evaluate the relationship between sample size and reported discovered foci in published VBM studies across different neuropsychiatric conditions so as to probe into the possibility of reporting biases affecting preferentially smaller studies. This was achieved by focusing on available voxel-based meta-analyses of VBM studies, such those performed with Activation Likelihood Estimate [Laird et al., 2005] or Signed Differential Mapping [Radua and Mataix-Cols, 2009, 2012; Radua et al., 2010a, 2012a]. These meta-analyses are attempting to reconcile contrasting and inconclusive individual VBM findings by obtaining larger sample sizes with an associated greater statistical power. Thus, we assess whether larger sample sizes are associated with larger number of identified foci. If conversely, the same or even more foci are claimed to be identified by small studies as with larger ones this would offer evidence for bias. The second aim of this study was to explore the impact of a number of variables on the relationship between sample size and number of reported foci in the VBM literature including the type of neuropsychiatric disorder, the publication year, the sample size of the study, the slice thickness of the images, the degree of smoothing, the software used to preprocess

or perform the statistical analysis of the data, the statistical threshold employed, and the use of a small volume corrections (SVC) in the analysis. Our third aim was then to evaluate whether sample size was related to the number of reported foci in meta-analyses of VBM studies across different psychiatric conditions and whether these meta-analyses report more or fewer foci than the much smaller studies that they include.

METHODS

Search Strategy

We conducted a four-step literature search. First, we searched on PubMed using the Boolean terms "voxel-based morphometry meta-analysis." All publications listed in PubMed prior to August 1, 2012 were included. In a second step we also searched the bibliographies of Brain Map (http://brainmap.org/pubs/) and SDM databases (http:// sdmproject.com) (last search performed on July 31, 2012). All eligible publications were included. In a third step we hand searched the references of the included publications to minimize the possibility of biases in the literature search. Full texts were pulled for all potentially eligible publications. Then the retrieved publications underwent an initial culling of ineligible and duplicate analyses. These publications were then hand searched for inclusion criteria and selected by two analysts independently (MF & PFP), with any discrepancies adjudicated until 100% rater agreement was achieved. To achieve a high standard of reporting we have adopted 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA) guidelines [Liberati et al., 2009].

In the final step, we searched and then collected all the individual studies listed in each included article.

Controlling for Independent Data

Many of the included articles conducted different metaanalyses for more than one condition (sub-meta-analyses). These sub-meta-analyses were each considered separately for inclusion in our study. To avoid inclusion of overlapping data, when two meta-analyses included overlapping sets of studies in a similar contrast, we retained only the more recent and largest number of studies/sample size meta-analysis. In the case where the same paper included both an overall meta-analysis and separate sub-analyses for different conditions, the sub-analyses were preferentially included (with the overall meta-analysis being considered a duplicate and excluded). As a consequence, all the included meta-analyses have addressed different between-groups contrasts. We then carefully searched the included articles at the level of each individual study and studies were compiled and compared a second time to eliminate overlapping samples to insure that no individual study was double counted.

Inclusion Criteria

Articles were included in our analysis if they were independent (see above) whole-brain voxel-based metaanalyses of magnetic resonance imaging (MRI) studies of human brain. Meta-analyses were eligible regardless of the neurological or psychiatric condition investigated. Exclusion criteria were (i) meta-analyses of ROI (not whole brain), (ii) structural modalities other than VBM (e.g., diffusion tensor imaging, cortical pattern matching), (iii) functional brain imaging meta-analyses or (iv) non-human studies, and (v) overlapping meta-analyses. Meta-analyses of studies investigating white matter differences (Peters et al., in press; Radua et al., 2010b) were also excluded. Only a minority of the retrieved meta-analyses had fully listed the number of subjects and number of foci identified in each individual study, which was necessary to perform the statistical analysis. To circumvent this problem, include moderators and avoid missing data, we collected all the individual studies for each meta-analysis and extracted these details (see below).

Data Extraction

At the level of each individual study, we extracted the total sample size, the overall number of foci, the condition, the contrast within the condition, the imaging parameters (magnet intensity, slice thickness, degree of smoothing, and software packages used), the statistical threshold [false discovery rate (FDR), family-wise error (FWE) correction, uncorrected *P*-value] and the use of SVC in the analysis. Similarly, at the level of the meta-analyses, we extracted total sample size, the overall number of foci, the condition, the contrast within the condition, the statistical threshold and the software packages used.

Theoretical Framework and Statistical Analysis

Given that studies with large samples have more power to detect abnormalities, the number of reported foci should show a positive relationship with the sample size. As exemplified in Figure 1, small studies should detect only a small proportion of the true abnormalities, whilst larger studies should detect a larger part of the true abnormalities. A weak or null relationship could indicate potential reporting biases affecting the smaller studies more than the larger studies [David et al., 2013].

Specifically, the relationship between the number of reported foci in each study and the sample size of the study was assessed with a zero-inflated Poisson regression [Zeleis et al., 2008]. This model was used, instead of simpler ones, because the number of foci in VBM studies was observed to follow a mixture of a point mass at zero with a count distribution. However, for the sake of completeness, we also conducted meta-analytical combination of Poisson coefficients, estimated separately for each published meta-analysis, simple Pearson correlations, non-linear Spearman correlations, Pearson correlations after discarding the most influential study according to the *dfbetas* statistic of the regression of foci by sample size [Belsley



Figure 1.

Expected relationship between sample size and number of abnormalities detected by whole-brain structural neuroimaging techniques.

Footnote: The number of abnormalities correctly detected as abnormal (P < 0.05) in a simulated study with that sample size is shown with solid lines. The number falsely detected abnormalities is shown with dotted lines. In all simulations, brain was composed of 5,000 independent parts, of which 95% were normal and 5% were abnormal.

et al., 1980], and meta-analytical combination of (Fishertransformed) Pearson correlations separately estimated per each published meta-analysis.

It should be noted that variability in the way authors report VBM results could conceal the expected positive relationship between the sample size and the number of reported foci. Statistically significant voxels are usually grouped in clusters of spatially contiguous voxels, and only the local maxima (i.e., foci) are reported. Importantly, an increase of the sample size helps non-significant voxels between two close clusters to achieve statistical significance, thus sometimes converting the two close clusters into a single larger one. The number of foci should not be affected by this conversion, but some authors choose to report only three foci per cluster. In other words, these authors could report up to six foci when describing the two close clusters, whilst no more than three when describing the single larger cluster obtained after an increase of the sample size. In such a case, the relationship between the sample size and the number of foci could be downwards biased.

A simulation framework was used to assess whether such potential bias could significantly affect the expected relationship. First, 84,000 gray-matter datasets were simulated by adding normally distributed noise to a normal graymatter template (n = 42,000 controls), or to a grav-matter template with abnormal volume in regions reported to have decreased gray matter in first psychotic episodes (n = 42,000patients) [Radua et al., 2012b]. Second, these data were smoothed with a large Gaussian kernel [$\sigma = 6$ mm, fullwidth at half maximum (FWHM) = 14 mm], thus simulating both the spatial covariance observable in raw data and the smoothing usually applied in VBM pre-processing. Finally, individuals were grouped in 400 simulated studies with different numbers of participants (from n = 10 to 200 per group), and standard group-level voxel-based statistics were performed (uncorrected P = 0.001, 20 voxels extent). As shown in Figure 2, the number of clusters followed a clear positive relationship with the sample size. The relationship would be the same if each cluster was substituted by three reported foci.

To explore experimental variables influencing the relationship between sample size and number of reported foci, subgroup regressions were conducted on the following subsets of studies: studies published up to and after 2008, studies with up to or more than six authors, studies with less than or at least 32 patients, studies with samples sizes up to 80 patients, studies conducted in MRI devices with magnets up to or stronger than 1.5 Tesla (T), studies with MRI acquisition slices thickness of at least or thinner than 1.5 mm, studies employing statistical parametric mapping (SPM) or other software packages to pre-process and compare the images, studies applying a smoothing of up to or superior to 8 mm of FWHM, studies thresholding at P < 0.001 uncorrected for multiple comparisons, studies thresholding at P < 0.05 FDR- or FWE-corrected for multiple comparisons, studies employing SVC, and studies investigating different neuropsychiatric conditions. Cutoffs for magnet intensity,



Figure 2.

Relationship between sample size and number of clusters in simulated VBM data.

slice thickness, and smoothing kernel were chosen because they allowed dividing the total sample of studies in two sub-groups of fairly similar size. The year 2008 was chose as cutoff to specifically test the impact of advanced VBM algorithms such as the DARTEL, which were introduced shortly before [Ashburner, 2007b]. The sample size of 32 patients was chosen on the basis of evidence indicating that the minimum sample size for a neuroimaging study is 16 patients per group [Friston, 2012]. The number of authors of six was chosen on the basis of the previous findings by Sayo et al (2011). Regression slopes of complementary subgroups with different findings (e.g., one slope is significantly higher than zero and the other slope is not significantly higher than zero) were formally compared with zero-inflated Poisson models. All calculations were performed with the "pscl" package for R [Jackman, 2012] [R_Development_Core_-Team, 2011]. A regression line was applied to the reported plots for both significant and non-significant relationships.

Finally, we also assessed the results of the meta-analyses that had combined these VBM studies. First, we evaluated the relationship between the number of reported foci in each meta-analysis and the combined sample size of the studies included in the meta-analysis with a Poisson regression. Again, this model was used, instead of simpler ones, because the number of foci in VBM studies was observed to follow a count distribution. For the sake of completeness, we also conducted simple Pearson correlation, non-linear Spearman correlation, and Pearson correlation after discarding the most influential study according to the *dfbetas* statistic of the regression of foci by sample size. Second, we evaluated whether the number of foci reported in the metaanalyses was larger or smaller than the number of foci reported in each of the VBM studies that they had combined. We tested the hypothesis that the much larger sample size of the meta-analyses would allow detecting more or at least as many foci as in the individual studies. In the presence of bias in single studies, the meta-analyses may report even fewer validated foci than the single studies, because the biases may be diluted in the meta-analysis. The analysis used the Wilcoxon paired test, where the number of foci in the meta-analysis was compared paired against the number of foci in each study that it included.

RESULTS

Database

Our literature search identified 54 full text articles, which were assessed for inclusion criteria. The final database comprised 42 articles with 79 meta-analyses (including sub-analyses). After checking for duplicate or overlapping meta-analyses, a final set of 47 meta-analyses were included and the final dataset used in this study comprised a total of 324 individual VBM studies. The literature search and the characteristics of the included and excluded meta-analyses are detailed in the Figure 3, Table I and Supporting Information Table IS. As shown in Table II, the number of participants ranged from 12 to 545 in the studies (median = 47, interquartile range = 39), and from 149 to 4087 in the meta-analyses (median = 534, interquartile range = 721). The median number of reported foci per study was six, while the median number of foci reported per meta-analysis was three. Seventy-four percent of the studies reported 10 foci or less, and 79% of the meta-analyses five foci or less. Other descriptive details of the included studies and meta-analyses are depicted in Table II.

Association Between Sample Size and Number of Foci in Individual VBM Studies

As shown in Table III and Figure 4, studies with larger sample sizes were found to report more abnormalities, but the slope was very small (2% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001), thus indicating potential reporting biases affecting the smaller studies more than the larger studies. Results were similar when using Pearson and Spearman correlations, when discarding statistically influential studies, or when combining Pearson correlations separately estimated per each published meta-analysis (simple Pearson r = 0.148, P = 0.004; Spearman rho = 0.139, P = 0.006; Pearson r without the most influential study = 0.176, P < 0.001; meta-analytically combined Pearson r = 0.110, P = 0.010). The binomial part of the zero-inflated Poisson regression was not found to be influenced by the sample size.

Effect of Moderators

No major differences according to the field (psychiatry or neurology, Supporting Information Fig. 1S) and clinical



Figure 3. PRISMA Flow chart of literature search.

conditions (Supporting Information Fig. 2S) were observed. With respect to methodological moderators the only subgroup where the regression between sample size and number of reported foci was relatively stronger was the set of studies with less than 32 patients (52% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001). The regression slope was nominally significant but small in studies with at least 32 patients (2% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001), with differences in regression slope between these two subgroups being

statistically significant (P < 0.001). The regression slope was small but still nominally significant in studies published up to 2008, in studies with more than six authors (Fig. 5), and in studies thresholding at P < 0.05 FWEcorrected for multiple comparisons (Fig. 6) (2–3% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001). Conversely, it was null in studies published after 2008, in studies with up to six authors, and in studies thresholding at P < 0.05 FDR-corrected for multiple comparisons (<1% increase in the number of foci per each 10-patient increase in sample-size, P > 0.05), with

Yang Bona2012 (Yang et al., 2012) 2010 (Bara et al., 2011) $P < 0.001$ Semantic dementia Bipolar disorderSD vs. HC FE Pas. HCBona2011 (Bara et al., 2012) $P < 0.001$ ShizophreniaSD vs. HC FE Pas. CHR.CCZBona2012 (Bara et al., 2012) $P < 0.001$ ShizophreniaSD vs. HC FE Pas. CHR.CCZBona2012 (Bara et al., 2012) $P < 0.001$ Depressive disorderEP vs. CHR.CCZBona2012 (Bara et al., 2012) $P < 0.001$ Depressive disorderEP vs. HC FE Pas. HCChen2010 (Chen and Ma.2010) $P < 0.001$ Depressive disorderER Pas. HC FE Pas. HCChen2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis risk.HR No.HC Chen HR FrantionChen2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis risk.HR No.HC Chen HR No.HCFusar-Poli2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis onsetEP vs. HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis risk.HR No.HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis onsetEP vs. HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis onsetEP vs. HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2011) $P < 0.001$ Payrbosis onsetEP vs. HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2012) $P < 0.001$ Payrbosis onsetEP vs. HC Chen HR No.HCLai2011 (Fusar-Poli et al., 2012	Author	Year	Statistical threshold	Condition	Contrast	Sample	Number of foci
boar 2010 (boar et al., 2011) $P < 0.001$ Bipolar disorder Bib vs. HC Boar 2011 (Boar et al., 2011) $P < 0.001$ Schizophrenia EF DP vs. HC EF DP vs. HC Boar 2012 (Boar et al., 2011) $P < 0.001$ Schizophrenia EF DP vs. HC EF DP vs. HC Boar 2012 (Boar et al., 2012) $P < 0.001$ Schizophrenia EF DP vs. HC EF DP vs. HC Boar 2011 (Fasar-Poli et al., 2011a) $P < 0.001$ Amyotrophic lateral sclerosis EF DP vs. HC EF DP vs. HC Chen and Ma 2010) $P < 0.001$ Amyotrophic lateral sclerosis EF DP vs. HC EF DP vs. HC Chan 2011 (Fasar-Poli et al., 2011a) $P < 0.001$ Psychosis risk. EF DP vs. HC Fisar-Poli 2011 (Fasar-Poli et al., 2011a) $P < 0.001$ Psychosis risk. EF DP vs. HC Liai 2011 (Fasar-Poli et al., 2011a) $P < 0.001$ Psychosis risk. EF PP vs. HE Liai 2011 (Fasar-Poli et al., 2011a) $P < 0.001$ Psychosis onset EF P vs. HE FF Vs. HC Liai 2011 (Fasar-Poli et al., 2011a)	Yang	2012 (Yang et al., 2012)	$P < 0.05 \; ({ m FDR})$	Semantic dementia	SD vs. HC	235	10
Bora 2011 (Bora et al., 2012) $P < 0.001$ Schizophrenia ECX vs. HC Bora 2012 (Bora et al., 2012) $P < 0.001$ Depressive disorder EPV vs. HC Bora 2012 (Bora et al., 2012) $P < 0.001$ Depressive disorder EPV vs. HC Bora 2012 (Bora et al., 2013) $P < 0.001$ Depressive disorder EPV vs. HC Chen 2011 (Fusar-Poli et al., 2011a) $P < 0.001$ Payrobisis risk MT DPV vs. HC Ebsar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Payrobisis risk MT DPV vs. HC Ebsar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Payrobisis risk MT DV ransition vs. HR Ebsar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Payrobisis risk HR vs. Scz. Ebsar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Payrobisis risk HR vs. Scz. Li 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Payrobisis risk HR vs. Scz. Li 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Payrobisis risk HR vs. Scz. Li	Bora	2010 (Bora et al., 2010)	P < 0.001	Bipolar disorder	BD vs. HC ef PD HC	1430 107	ю ғ
Decision 2012 (Bora et al., 2012) $P < 0.001$ Depressive disorder ETS N: ETS N: EDP vs. CHR SC2 Bora 2012 (Bora et al., 2012) $P < 0.001$ Depressive disorder ETDP vs. HC Chen 2010 (Chen and Ma 2010) $P < 0.001$ Depressive disorder ETDP vs. HC Chen 2010 (Chen and Ma 2010) $P < 0.001$ Amyotrophic lateral sclerosis ETDP vs. HC Chen 2011 (Fusar-Poli et al., 2011a) $P < 0.001$ Amyotrophic lateral sclerosis ETDP vs. HC Fisar-Poli 2011 (Fusar-Poli et al., 2011a) $P < 0.001$ Brychosis risk ETDP vs. HC Fisar-Poli et al., 2011) $P < 0.001$ Brychosis onst ETD vs. HC ETD vs. HC Lai 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Brychosis onst ETD vs. HC Lai 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Brychosis onst ETD vs. HC Lai 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Brychosis onst ETD vs. HC Lai 2011 (Fusar-Poli et al., 2012) $P < 0.001$ Brychosis onst ETD vs. HC Lai	Bora	2011 (Bora et al 2011)	P < 0.001	Schizonhrenia	FE BU VS. HC SC7 vs. HC	197 4087	- r
Bora2012 (Bora et al., 2012) $P < 0.001$ Depressive disorderRFP vs. KIC RE DFP vs. IIC RE DFP vs. IIC RE DFP vs. IIC RE DFP vs. IIC RE DFP vs. IIC C ANX vs. IIC NO CO ANX vs. IIC 	POIR		10000 / 1	Actitzo principa	FEP vs. HC	874	20
Bora 2012 (Bora et al., 2012) $7 < 0.001$ Depressive disorder ED EP vs. HC COS ANY vs. HC OC ANY vs. HC COS A					FEP vs. CHR SCZ	4087	1 ന
Chen MID EP vs. HC Fib DEP vs. HC Fib DEP vs. HC Fib DEP vs. HC Fib DEP vs. HC Fib DEP vs. HC No Navs. HC Fib Navs. HC No Navs. HC D11 (Fib Sar-Poli et al., 2011b) $P < 0.001$ Bychosis risk. HR Nofmastion vs. HC Constraint Rvs. HC HR vs. HC HS Nofmastion vs. HC Constraint Rvs. HC D11 (Fib Sar-Poli et al., 2012) $P < 0.001$ D2012 (Particle rat., 2012) $P < 0.001$ Modinos 2012 (Nadvo et al., 2012) Nakelockschat 2011 (Nakse et al., 2012) Strond Mid orgenitive impairment Nikelockschat 2012 (Natse et al., 2012) P < 0.001	Bora	2012 (Bora et al., 2012)	P < 0.001	Depressive disorder	FE DEP vs. HC	292	1
Chen Fie DPF Tusar-Poli et al., 2010) $P < 0.001$ P < 0.001Amyotrophic lateral sderosis Pychosis riskFE DPF CO ANX vs. HC C DAY vs. HC N CO ANX vs. HC C Diradi HR vs. HC C diradi HR vs. HC C diradi HR vs. HC C diradi HR vs. HC Erender HX vs. Clinical HR HX vs. SCZ C diradi HR vs. HC C diradi HR vs. HC D vs. HC C diradi HR vs. HC C diradi HR vs. HC C diradi HR vs. HC NGH-Jockschat 2012 (Rudu et al. 2013) P < 0.001 RichhanADHD D vs. HC ADHD vs. HC ADD vs. HC ADHD vs. HC ADD vs. HC AD				1	ME DEP vs. HC	1631	7
Chem2010 (Chen and Ma 2010) $P < 0.001$ Amyotrophic lateral sclerosisCO ANX vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.001$ Amyotrophic lateral sclerosisCDF vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.001$ Amyotrophic lateral sclerosisCDF vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Rychosis riskHR vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Rychosis onsetFR vs. HCLai2011 (Ani 2011) $P < 0.001$ Panic disorderFR vs. HCLai2012 (Falaniyappan et al., 2012) $P < 0.001$ Panic disorderFR vs. HCLai2012 (Ralaniyappan et al., 2012) $P < 0.001$ Panic disorderFR vs. HCNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDNDHDNickl-Jockschat et al., 2013) $P < 0.001$ ADHDNDHDNDHDNickl-Jockschat et al., 2013) $P < 0.001$ ADHDNDHDNDHD vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDNDHDNDHD vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDNDHDNDHD vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDNDHDND vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDND vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDND vs. HCNickl-Jockschat et al., 2013) $P < 0.001$ ADHDND vs. HCNickl-Jockschat <td< td=""><td></td><td></td><td></td><td></td><td>FE DEP vs. ME DEP</td><td>1923</td><td>1</td></td<>					FE DEP vs. ME DEP	1923	1
Chen2010 (Chen and Ma 2010) $P < 0.001$ Amyotrophic lateral sclerosisNOC OANV vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.05$ (FDK)Psychosis riskNOC OANV vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.05$ (FDK)Psychosis riskAl5 vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.05$ (FDK)Psychosis riskHR vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetHR vs. HCLai2011 (Lai 2011) $P < 0.001$ Psychosis onsetHR vs. ACLai2011 (Lai 2011) $P < 0.001$ Princi disorderPris, HRLai2012 (Palaniyappan et al., 2012) $P < 0.001$ Princi disorderPris, HRNodimos2012 (Nodinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsATLF vs. HCNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDNors, HCNOHSNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDNDHDNDHDNickl-Jockschat2012 (Nickloan et al., 2012) $P < 0.001$ ADHDNDHDNDHDNickl-Jockschat2012 (Nickloan et al., 2012) $P < 0.001$ ADHD					CO ANX vs. HC	1117	1
					NO CO ANX vs. HC	558	0
Chen2010 (Chen and Ma 2010) $P < 0.001$ Amyotrophic lateral sclerosisAll Sv. HCFusar-Poli et al., 2011 $P < 0.05$ (FDR)Psychosis riskHR vs. HCEusar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HCEusar-Poli 2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HCLai2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HCLai2011 (Fusar-Poli et al., 2012) $P < 0.001$ Panic disorderPN vs. HCLi2012 (Palaniyapan et al., 2012) $P < 0.001$ Panic disorderPD vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Andiroy verbal hallucinationsATH Severe vs. AVHs Non severeNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHD vs. HCADH vs. HCNakao2012 (Rotal et al., 2012b) $P < 0.001$ ADHDADHD vs. HCADH vs. HCNakao2012 (Rotal et al., 2012b) $P < 0.001$ ADHDADHD vs. HCADH vs. HCNakao2012 (Rotal et al., 2012b) $P < 0.001$ ADHDADH vs. HCADH vs. HCRadua2012 (Rotal et al., 2012b) $P < 0.001$ ADHDADH vs. HCADH vs. HCRadua2012 (Rotal et al., 2012b) $P < 0.001$ ADHDADH vs. HCADH vs. HCRadua2012 (Rotal et al., 2012b) $P < 0.001$ BV-Front temporal demetriaBV-FrD vs. HCRadua2012 (Rotal et al., 2012b) $P < 0.001$ ADH vs. HCADH vs. HC <t< td=""><td></td><td></td><td></td><td></td><td>C DEP vs. HC</td><td>1414</td><td>1</td></t<>					C DEP vs. HC	1414	1
Fusar-Poli2011 (Fusar-Poli et al., 2011a) $P < 0.05$ (FDR)Psychosis riskClinical HR vs. HCFusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HCGenetic HR vs. Clinical HRHR vs. FCGenetic HR vs. Clinical HRLai2011 (Lai 2011) $P < 0.001$ Psychosis onsetFEP vs. HCLai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HCLai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HCModinos2012 (Malaniyappan et al., 2012) $P < 0.001$ Panic disorderPD vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsSCZ NVHs vs. SCZ No AVHsNakoo2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDAVHS Severe vs. AVHs Non severeSoluck-Jockschat2012 (Nicki-Jockschat et al., 2012) $P < 0.001$ ADHDADHDAVHS Vs. HCNakoo2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDAVHS VS. SCZ No AVHSNako2012 (Nicki-Jockschat et al., 2012) $P < 0.001$ ADHDADHD vs. HCPan2012 (Nicki-Jockschat et al., 2012) $P < 0.001$ BV-fronto temporal dementiaBV-FID vs. HCPan2012 (Ran, 2012) $P < 0.001$ BV-fronto temporal dementiaBV-FID vs. HCPan2012 (Ran, 2012) $P < 0.001$ ADHDADHD vs. HCPan2012 (Ran, 2012) $P < 0.001$ AntisersePV vs. HCPan2012 (Ran, 2012) $P < 0.001$ </td <td>Chen</td> <td>2010 (Chen and Ma 2010)</td> <td>P < 0.001</td> <td>Amyotrophic lateral sclerosis</td> <td>ALS vs. HC</td> <td>165</td> <td>1</td>	Chen	2010 (Chen and Ma 2010)	P < 0.001	Amyotrophic lateral sclerosis	ALS vs. HC	165	1
Fusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetHR NGTransition vs. HR Transition Genetic HR vs. Clinical HR HR vs. SCZLai2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HR EVs. HCLai2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderFEP vs. HR EVs. HCLai2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderFEP vs. HR EVs. HCModinos2013 (Modinos et al., 2012) $P < 0.001$ Panic disorderNHS Sever vs. AVHS Non severeNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDADHD vs. HCNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDADHD vs. HCNakao2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDADHD vs. HCNickl-Jockschat2012 (Richlan et al., 2012) $P < 0.001$ ADHDADHD vs. HCRadua2013 (Ricklan et al., 2012) $P < 0.001$ ADHDADHD vs. HCRadua2013 (Richlan et al., 2012) $P < 0.001$ ADHDADHD vs. HCSchreeter2003 (Schreeter et al., 2013) $P < 0.001$ ADHDADHD vs. HCSchreeter2013 (Richlan et al., 2012) $P < 0.001$ ADHDADHS vs. HCSchreeter2013 (Richlan et al., 2012) $P < 0.001$ ADHSADHS vs. HCSchreeter2013 (Richlan et al., 2011) $P < 0.001$ ADHEADHS vs. HCSchreeter2013 (Richlan et al., 2011) $P < 0.001$ ADHSADHS <td>Fusar-Poli</td> <td>2011 (Fusar-Poli et al., 2011a)</td> <td>P < 0.05 (FDR)</td> <td>Psychosis risk</td> <td>Clinical HR vs. HC</td> <td>516</td> <td>ß</td>	Fusar-Poli	2011 (Fusar-Poli et al., 2011a)	P < 0.05 (FDR)	Psychosis risk	Clinical HR vs. HC	516	ß
Fusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetGenetic HR vs. HC Genetic HR vs. GZLai2011 (Lai 2011) $P < 0.001$ Psychosis onsetFEP vs. HC HR vs. SCZLai2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderPR vs. HC HR vs. SCZModinos2012 (Modinos et al., 2012) $P < 0.001$ Panic disorderPL vs. HC FL vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ ADHDAuditory verbal hallucinationsNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDNickl-Jockschat2012 (Nacko et al., 2012) $P < 0.001$ ADHDNickl-Jockschat2012 (Rickl-Jockschat et al., 2012) $P < 0.001$ ADHDNickl-Jockschat2012 (Ran, 2012b) $P < 0.001$ ADHDNickl-Jockschat2012 (Ran, 2012b) $P < 0.001$ ADHDNickl-Jockschat2012 (Radu at al., 2012) $P < 0.001$ ADHDNickl-Jockschat2013 (Ridha et al., 2012) $P < 0.001$ ADHDSchneeter2013 (Ridha et al., 2012) $P < 0.001$ ADHDSchneeter2013 (Nia et al., 2012) $P < 0.0001$ ADHDSchneeter2013 (Nia et al., 2012) $P < 0.0001$ ADHDSchneeter2013 (Nia et al., 2012) $P < 0.0001$ ADHDSchneeter2013 (Nia et al., 2012) $P < 0.005$ DyslexiaSchneeter2013 (Nia et al., 2012) $P < 0.005$ DyslexiaSchneeter2013 (Nia et al., 2011) $P < 0.005$ ADHD <td></td> <td></td> <td></td> <td></td> <td>HR NoTransition vs. HR Transition</td> <td>165</td> <td>5</td>					HR NoTransition vs. HR Transition	165	5
Fusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetEer vs. HR FEP vs. HCLai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HCLi2012 (Falaniyappan et al., 2012) $P < 0.001$ Panic disorderFEP vs. HCModinos2012 (Nakao et al., 2012) $P < 0.001$ Panic disorderPD vs. HCModinos2011 (Nakao et al., 2012) $P < 0.001$ ADHDAVHSNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDAVHSNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDNickl-Jockschat2012 (Ran, 2012a) $P < 0.001$ ADHDNickl-Jockschat2012 (Ran, 2012a) $P < 0.001$ ADHDNickl-Jockschat2012 (Ran, 2012a) $P < 0.001$ Mild cognitive impairmentMCI vs. HCPan2012 (Ran, 2012a) $P < 0.001$ BV-from temporal dementiaBV-from s. HCPan2012 (Ran, 2012a) $P < 0.001$ Aniety disordersOCD vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ Aniety disordersOCD vs. HCSchroeter2003 (Schroeter et al., 2012) $P < 0.001$ Aniety disordersOCD vs. HCSchroeter2013 (Nia et al., 2012) $P < 0.001$ Aniety disordersOCD vs. HCSchroeter2013 (Richan et al., 2012) $P < 0.001$ Aniety disordersOCD vs. HCSchroeter2013 (Richan et al., 2012) $P < 0.001$ Aniety disorderOCD vs. HCSchroeter2011 (Via et al., 2011)					Genetic HR vs. HC	952	С
Fusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetHR vs. SCZLai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HCLi2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderFD vs. HCModinos2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderPD vs. HCModinos2012 (Nakao et al., 2011) $P < 0.001$ Auditory verbal hallucinationsAVHS severe vs. AVHS Non severeNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDAVHDAVHS severe vs. AVHS Non severeNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDAVHSNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDAVHSNickl-Jockschat2012 (Ran, 2012b) $P < 0.001$ ADHDAVHSNickl-Jockschat2012 (Ran, 2012b) $P < 0.001$ ADHDAVHSNickl-Jockschat2012 (Ran, 2012b) $P < 0.001$ ANHSAVHSPan2012 (Ran, 2012b) $P < 0.001$ ANHSANHSSchreeter2010 (Radua et al. 2010a) $P < 0.001$ Anvistoria formentiaDV-TVS. HCRadua2012 (Ran, 2012b) $P < 0.001$ Anvistoria formentiaDV-S NCSchreeter2010 (Radua et al. 2010a) $P < 0.001$ AnvistoriaDV-S NCSchreeter2010 (Radua et al. 2010a) $P < 0.001$ AnvistoriaDV-S NCSchreeter2010 (Schreet et al. 2010a) $P < 0.001$ AnvistoriaDV-S NC <t< td=""><td></td><td></td><td></td><td></td><td>Genetic HR vs. Clinical HR</td><td>1468</td><td>2</td></t<>					Genetic HR vs. Clinical HR	1468	2
Fusar-Poli2011 (Fusar-Poli et al., 2011b) $P < 0.001$ Psychosis onsetFEP vs. HCLai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HCLi2012 (Palaniyappan et al., 2012) $P < 0.001$ Panic disorderPros. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Panic disorderRTLE vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsSCZ No AVHsNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDSCZ No AVHsNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDMCI vs. HCNickl-Jockschat2012 (Pan., 2012a) $P < 0.001$ ADHDMCI vs. HCNickl-Jockschat2012 (Radua et al., 2012a) $P < 0.001$ ADHDMCI vs. HCPan2012 (Radua et al., 2012a) $P < 0.001$ ADHDMCI vs. HCPan2012 (Radua et al., 2012a) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCPan2012 (Radua et al., 2012a) $P < 0.001$ DyslexiaDYL vs. HCPan2013 (Richlan et al., 2012a) $P < 0.005$ DyslexiaDYL vs. HCCorbo vs. Orbo vs. OrboDyslexiaDyl vs. HCDOD vs. HCPan2013 (Richlan et al., 2011) $P < 0.005$ DylslexiaDyl vs. HCPan2013 (Richlan et al., 2011) $P < 0.005$ DylslexiaDyl vs. HCPan2013 (Richlan et al., 2011) $P < 0.005$ DylslexiaDyl vs. HCPan2013 (Richlan et al., 20					HR vs. SCZ	754	2
Lai2011 (Lai 2011) $P < 0.001$ Panic disorderFEP vs. HRLi2012 (Palaniyappan et al., 2012) $P < 0.05$ (FDR)EpilepsyFTLE vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsSTLE vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ AUHDRTLE vs. HCNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDANHS Sevre vs. AVHS Non severeNakao2011 (Nakao et al., 2012) $P < 0.001$ ADHDADHDNickl-Jockschat2012 (Pan, 2012b) $P < 0.001$ ADHDADHD vs. HCNa2012 (Pan, 2012b) $P < 0.001$ ADHDADHD vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCPan2012 (Radua et al. 2013) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCPan2012 (Richlan et al., 2013) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCPan2012 (Richlan et al., 2013) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCPan2013 (Richlan et al., 2013) $P < 0.005$ DyslexiaDVL vs. HCPan2013 (Richlan et al., 2013) $P < 0.005$ DyslexiaDVL vs. HCPan2013 (Richlan et al., 2013) $P < 0.005$ DyslexiaDVL vs. HCPan2013 (Richlan et al., 2013) $P < 0.005$ DyslexiaDVL vs. HC<	Fusar-Poli	2011 (Fusar-Poli et al., 2011b)	P < 0.001	Psychosis onset	FEP vs. HC	413	С
Lai2011 (Lai 2011) $P < 0.001$ Panic disorderPD vs. HCLi2012 (Palaniyappan et al., 2012) $P < 0.05$ (FDR)EpilepsyRTLE vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsRTLE vs. HCModinos2011 (Nakao et al., 2011) $P < 0.001$ ADHDSCZ AVHs vs. SCZ No AVHsNakao2011 (Nakao et al., 2011) $P < 0.001$ ADHDMild cognitive impairmentADHD vs. HCNickl-Jockschat2012 (Nickl-Jockschat et al., 2012) $P < 0.001$ ADHDMIL vs. HCNickl-Jockschat et al., 2012) $P < 0.001$ ADHDMild cognitive impairmentMC vs. HCNickl-Jockschat et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCPan2012 (Pan et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2010 (Radua et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2012 (Richlan et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCSchroeter2009 (Schroeter et al., 2013) $P < 0.001$ Anxiety disordersOAD vs. HCSchroeter2009 (Schroeter et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCSchroeter2012 (Ni et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCSchroeter2009 (Schroeter et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCSchroeter2010 (Vi et al., 2011) $P < 0.005$ (FDR)Alzheimer's					FEP vs. HR	865	4
Li2012 (Palaniyappan et al., 2012) $P < 0.05$ (FDR)EpilepsyRTLE vs. HCModinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsRTLE vs. HCMakao2011 (Nakao et al., 2011) $P < 0.001$ ADHDADHDSZ AVHS vs. SZZ No AVHSNakao2011 (Nakao et al., 2012) $P < 0.05$ (n.a.)Mild cognitive impairmentADHD vs. HCNickl-jockschat2012 (Roickl-jockschat et al., 2012) $P < 0.05$ (n.a.)Mild cognitive impairmentMCI vs. HCPan2012 (Pan, 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCPan2012 (Rain, 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCRadua2010 (Radua et al., 2010) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCSchroeter2003 (Schroeter et al., 2012) $P < 0.0001$ Antiety disordersOCD vs. ICSchroeter2012 (Richlan et al., 2011) $P < 0.0001$ Antiethere's diseaseAD vs. HCSchroeter2012 (Richlan et al., 2011) $P < 0.0001$ Antiethere's diseaseAD vs. HCSchroeter2012 (Richlan et al., 2011) $P < 0.0001$ AD vs. HCAD vs. HCSchroeter2012 (Richlan et al., 2011) $P < 0.0001$ AD vs. HCAD vs. HCSchroeter2012 (Richlan et al., 2011) $P < 0.0001$ AD vs. HCAD vs. HCSchroeter2012 (Richlan et al., 2011) $P < 0.$	Lai	2011 (Lai 2011)	P < 0.001	Panic disorder	PD vs. HC	226	7
Modinos2012 (Modinos et al., 2012) $P < 0.001$ Auditory verbal hallucinationsLTLE vs. HCNakao2011 (Nakao et al., 2011) $P < 0.001$ ADHDADHDSevere vs. AVHs Non severeNickl-Jockschat2012 (Nickl-Jockschat et al., 2012b) $P < 0.05$ (n.a)Mild cognitive impairmentADHD vs. HCNickl-Jockschat2012 (Pan, et al., 2012a) $P < 0.05$ (n.a)Mild cognitive impairmentMCI vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaMCI vs. HCPan2012 (Pan, 2012b) $P < 0.001$ ADHDADHD vs. HCPan2012 (Radua et al., 2012) $P < 0.001$ ANVertonto temporal dementiaBV-FTD vs. HCConstruct2010 (Radua et al., 2012) $P < 0.001$ Anxiety disordersOAD vs. HCColorer2010 (Schroeter et al., 2012) $P < 0.001$ Alzheimer's diseaseADV vs. HCSchroeter2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseADV vs. HCColor vs. OADNutsion Spectrum DisorderADV vs. HCADVs. HCVia2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseADV vs. HCCheng2012 (Zheng et al., 2011) $P < 0.001$ Alzheimer's diseaseADV vs. HCZheng2012 (Zheng et al., 2010) $P < 0.005$ (FDR)HortisorderADV vs. HCZheng2010 (Vi et al., 2010) $P < 0.005$ (FDR)HortisorderADV vs. HCZheng2012 (Ni et al., 2010) $P < 0.005$ (FDR)HortisorderADV vs. HCZheng<	Li	2012 (Palaniyappan et al., 2012)	P < 0.05 (FDR)	Epilepsy	RTLE vs. HC	300	4
					LTLE vs. HC	433	11
Nakao2011 (Nakao et al., 2011) $P < 0.001$ ADHDSCZ AVHs vs. SCZ No AVHsNickl-Jockschat2012 (Nickl-Jockschat et al., 2012b) $P < 0.05$ (n.a.)Mild cognitive impairmentADHD vs. HCPan2012 (Pan et al., 2012b) $P < 0.001$ BV-Fronto temporal dementiaMCI vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto temporal dementiaPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ BV-Fronto temporal dementiaBV-Fronto vs. HCRadua2012 (Richlan et al., 2012) $P < 0.001$ Anxiety disordersOAD vs. HCRichlan2012 (Richlan et al., 2011) $P < 0.001$ Anxiety disordersOAD vs. HCSchroeter2009 (Schroeter et al., 2011) $P < 0.001$ Alzheimer's diseaseDYL vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseDYL vs. HCAnnes2010 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseDYL vs. HCZheng2010 (Yu et al., 2011) $P < 0.001$ Alzheimer's diseaseDYL vs. HCZheng2010 (Yu et al., 2010) $P < 0.001$ Alzheimer's diseaseDYL vs. HCZheng2010 (Yu et al., 2010) $P < 0.005$ (FDR)Focal dystoniaDYT vs. MCZheng2010 (Yu et al., 2010) $P < 0.005$ (FDR)Bipolar disorder and schizophrenia </td <td>Modinos</td> <td>2012 (Modinos et al., 2012)</td> <td>P < 0.001</td> <td>Auditory verbal hallucinations</td> <td>AVHs Severe vs. AVHs Non severe</td> <td>259</td> <td>9</td>	Modinos	2012 (Modinos et al., 2012)	P < 0.001	Auditory verbal hallucinations	AVHs Severe vs. AVHs Non severe	259	9
Nakao2011 (Nakao et al., 2011) $P < 0.001$ ADHDADHDADHD vs. HCNickl-Jockschat2012 (Nickl-Jockschat et al., 2012b) $P < 0.05$ (n.a.)Mild cognitive impairmentMCI vs. HCPan2012 (Pan et al., 2012a)n.a.Parkinson's diseasePKD vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2010 (Radua et al., 2012a) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2010 (Radua et al., 2012) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2012 (Richlan et al., 2012) $P < 0.001$ Anxiety disordersOCD vs. ACRichlan2012 (Richlan et al., 2011) $P < 0.0001$ Anxiety disordersOCD vs. ACSchroeter2009 (Schroeter et al., 2011) $P < 0.0001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.0001$ Alzheimer's diseaseAD vs. HCZheng2012 (Zheng et al., 2011) $P < 0.001$ Autism Spectrum DisorderAD vs. HCZheng2012 (Zheng et al., 2011) $P < 0.05$ (FDR)Focal dystoniaDYL vs. ASPZheng2010 (Yu et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. MCZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Focal dystoniaDYT vs. MCZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)MC vs. MCADU vs. MCZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)MC vs. MCADU vs. MCZheng <td></td> <td></td> <td></td> <td></td> <td>SCZ AVHs vs. SCZ No AVHs</td> <td>266</td> <td>0</td>					SCZ AVHs vs. SCZ No AVHs	266	0
Nickl-Jockschat2012 (Nickl-Jockschat et al., 2012b) $P < 0.05$ (n.a.)Mild cognitive impairmentMCI vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FFID vs. HCPan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FFID vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ BV-Fronto temporal dementiaBV-FFID vs. HCRadua2012 (Richlan et al., 2012) $P < 0.001$ Anxiety disordersOCD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.001$ Alzheimer's diseaseDYL vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.001$ Alzheimer's diseaseAD vs. HCSchroeter2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCZheng2012 (Zheng et al., 2012) $P < 0.001$ Alzheimer's diseaseAD vs. HCZheng2010 (Yu et al., 2011) $P < 0.05$ (FDR)Focal dystoniaDYL vs. HCZheng2010 (Yu et al., 2011) $P < 0.05$ (FDR)Rocal dystoniaBD vs. SCZZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Mild coentier end schizophreniaBD vr. SCZZut2010 (Yu et al., 2010) $P < 0.05$ (FDR)Mild coentier innointentMCI vs. MCI st	Nakao	2011 (Nakao et al., 2011)	P < 0.001	ADHD	ADHD vs. HC	722	2
Pan2012 (Pan et al., 2012a)n.a.Parkinson's diseaseAmmestic MCI vs. HCPan2012 (Pan,, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.001$ Anxiety disordersOCD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.001$ Alzheimer's diseaseDV vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCTheng2012 (Zheng et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCTheng2012 (Zheng et al., 2010) $P < 0.001$ Altism Spectrum DisorderASD vs. ADU ASDTheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ADU ASDTheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBV vs. SCZTeneira2011 (Ferreira et al., 2010) $P < 0.05$ (FDR)Mild convirtive innovintive innovintintive innovintive innovintive innov	Nickl-Jockschat	2012 (Nickl-Jockschat et al., 2012b)	P < 0.05 (n.a.)	Mild cognitive impairment	MCI vs. HC	1726	ю
Pan2012 (Pan et al., 2012a)n.a.Parkinson's diseasePKD vs. HCPan2012 (Pan,, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ BV-Fronto temporal dementiaBV-FrD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.001$ Anxiety disordersOCD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.005$ DyslexiaDyslexiaSchroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderAD vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.001$ Autism Spectrum DisorderAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Rutism Spectrum DisorderAD vs. HCZheng2012 (Zheng et al., 2010) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (FDR) $P < 0.01$ (FDR)Mild cornitive innaimenttMCI conv vs. MCI st					Amnestic MCI vs. HC	1659	ß
Pan2012 (Pan, 2012b) $P < 0.001$ BV-Fronto temporal dementiaBV-FTD vs. HCRadua2010 (Radua et al. 2010a) $P < 0.001$ Anxiety disordersOCD vs. HCRichlan2012 (Richlan et al. 2012) $P < 0.005$ DyslexiaOCD vs. HCRichlan2012 (Richlan et al. 2012) $P < 0.005$ DyslexiaOCD vs. HCSchroeter2009 (Schroeter et al. 2009) $P < 0.0001$ Alzheimer's diseaseDYL vs. HCSchroeter2009 (Schroeter et al. 2009) $P < 0.0001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al. 2011) $P < 0.001$ Autism Spectrum DisorderAD vs. HCZheng2012 (Zheng et al. 2012) $P < 0.001$ Autism Spectrum DisorderASD vs. HCZheng2010 (Yu et al. 2010) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2010 (Yu et al. 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (FDR) $P < 0.01$ (FDR)Mild cornitive innaimenttMCI conv. NCI st	Pan	2012 (Pan et al., 2012a)	n.a.	Parkinson's disease	PKD vs. HC	873	1
Radua2010 (Radua et al. 2010a) $P < 0.001$ Anxiety disordersOCD vs. HCRichlan2012 (Richlan et al., 2012) $P < 0.005$ DyslexiaOAD vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseDYL vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderAD vs. HCSchroeter2000 (Schroeter et al., 2009) $P < 0.001$ Autism Spectrum DisorderAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderAD vs. HCZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (Farreira et al., 2011) $P < 0.01$ (FDR)Mild cornitive innairmentMCI conv. S. MCI st	Pan	2012 (Pan., 2012b)	P < 0.001	BV-Fronto temporal dementia	BV-FTD vs. HC	534	1
Richlan2012 (Richlan et al., 2012) $P < 0.005$ DyslexiaOAD vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseDYL vs. HCSchroeter2001 (Via et al., 2011) $P < 0.001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderASD vs. HCZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFerreira2011 (Ferreira et al., 2011) $P < 0.01$ (FDR)Mild cornitive innairmentMCI conv. MCI st	Radua	2010 (Radua et al. 2010a)	P < 0.001	Anxiety disorders	OCD vs. HC	836	4
Richlan2012 (Richlan et al., 2012) $P < 0.005$ DyslexiaOCD vs. OADSchroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseDYL vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderASD vs. HCVia2012 (Zheng et al., 2012) $P < 0.001$ Autism Spectrum DisorderASD vs. HCZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (Farreira et al., 2011) $P < 0.01$ (FDR)Mild coorritive innairmentMCI conv. MCI st					OAD vs. HC	483	С
Richlan2012 (Richlan et al., 2012) $P < 0.005$ DyslexiaDylL vs. HCSchroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderASD vs. HCVia2011 (Via et al., 2012) $P < 0.001$ Autism Spectrum DisorderASD vs. HCAUT vs. ASPAUT vs. ASPCHI ASD vs. ADU ASDZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaZu2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (Farreira et al. 2011) $P < 0.01$ (FDR)Mild coornitive innairmentMCI conv. MCI st					OCD vs. OAD	1376	С
Schroeter2009 (Schroeter et al., 2009) $P < 0.0001$ Alzheimer's diseaseAD vs. HCVia2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderASD vs. HCVia2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. ASPZheng2012 (Zheng et al., 2010) $P < 0.05$ (FDR)Focal dystoniaDYT vs. HCFarreira2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFarreira2011 (Farreira et al., 2011) $P < 0.01$ (FDR)Mild coortive innairmentMCI conv vs. MCI st	Richlan	2012 (Richlan et al., 2012)	P < 0.005	Dyslexia	DYL vs. HC	266	ß
Via2011 (Via et al., 2011) $P < 0.001$ Autism Spectrum DisorderASD vs. HCAUT vs. ASPAUT vs. ASPZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. HCYu2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZEnreira2011 (Ferreira et al., 2011) $P < 0.01$ (FDR)Mild coortifive innairmentMCI conv vs. MCI st	Schroeter	2009 (Schroeter et al., 2009)	P < 0.0001	Alzheimer's disease	AD vs. HC	421	9
Zheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaAUT vs. ASPZheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. HCYu2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZEvereira2011 (Ferreira et al. 2011) $P < 0.07$ (FDR)Mild coortitive innairmentMCI conv vs. MCI st	Via	2011 (Via et al., 2011)	P < 0.001	Autism Spectrum Disorder	ASD vs. HC	967	ß
Zheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaCHI ASD vs. ADU ASDZu2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFerreira2011 (Ferreira et al. 2011) $P < 0.01$ (FDR)Mild cornitive immainmentMCI conv vs. MCI st				4	AUT vs. ASP	905	0
Zheng2012 (Zheng et al., 2012) $P < 0.05$ (FDR)Focal dystoniaDYT vs. HCYu2010 (Yu et al., 2010) $P < 0.05$ (FDR)Bipolar disorder and schizophreniaBD vs. SCZFerreira2011 (Ferreira et al., 2011) $P < 0.01$ (FDR)Mild coorditive inmainmentMCI conv vs. MCI st					CHI ASD vs. ADU ASD	967	1
Yu 2010 (Yu et al., 2010) $P < 0.05$ (FDR) Bipolar disorder and schizophrenia BD vs. SCZ Ferreira 2011 (Ferreira et al. 2011) $P < 0.01$ (FDR) Mild coorditive invariament MCI conv vs. MCI st	Zheng	2012 (Zheng et al., 2012)	P < 0.05 (FDR)	Focal dystonia	DYT vs. HC	446	ß
Earraira 2011 (Ferreira et al. 2011) $P < 0.01$ (FDR) Mild coonitive impairment MCI conv. vs. MCI st	Yu	2010 (Yu et al., 2010)	P < 0.05 (FDR)	Bipolar disorder and schizophrenia	BD vs. SCZ	2617	23
	Ferreira	2011 (Ferreira et al 2011)	P < 0.01 (FDR)	Mild conitive impairment	MCT conv. vs. MCT st	479	- 1

***** 3058 *****

Author	Year	Statistical threshold	Condition	Contrast	Sample	Number of foci
Yu	2011 (Yu et al., 2011)	P < 0.05 (FDR)	Autism spectrum disorder	AUT vs. HC	343	24
		~	٩	ASP vs. HC	374	13
Frodl	2012 (Frodl and Skokauskas 2012)	P < 0.001	ADHD	CHI ADHD vs. HC	348	7
				ADU ADHD vs. HC	260	7
Rotge	2010 (Rotge et al., 2010)	P < 0.05 (FDR)	OCD	CHI OCD vs. HC	149	16
))			ADU OCD vs. HC	512	13

CHI = children; CHR = chronic; CO ANX = comorbid anxiety; conv = converters; DEP = depressive disorder; DYL = dyslexia; DYT = dystonia; FDR = false discovery rate; FE = first episode; FEP = first episode psychosis; HC = healthy controls; HR = high risk; LTLE = left temporal lobe epilepsy; MCI = mild cognitive impairment; n.a. = non RTLE = right temporal lobe epilepsy; available; OAD = other anxiety disorders; OCD = obsessive-compulsive disorder; PD = panic disorder; PKD = Parkinson's disease; SCZ = schizophrenia; SD = semantic dementia; st = stable

differences in regression slope between these pairs of subgroups being statistically significant ($P \le 0.005$ in all cases).

There were no significant differences in the other methodological subgroups (up to 80 patients, studies with magnets up to 1.5T, studies with magnets stronger than 1.5T, MRI slices of 1.5 mm or more, MRI slices inferior to 1.5 mm, SPM used for pre-processing, other software used for pre-processing, FWHM of 8 mm or less, FWHM superior to 8 mm, SPM used for statistics, other software used for statistics, no correction for multiple comparisons, use of SVC, and no use of SVC). Similarly, exclusion of foci detected with SVC from the main analysis did not change the main results (2% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001; Pearson r = 0.138, P = 0.007; Spearman rho = 0.113, P = 0.023; Pearson r without the most influential study = 0.166, P = 0.002).

Association Between Sample Size and Number of Foci in VBM Meta-Analyses

The regression was not nominally significant when meta-analyses, rather than individual studies, were analyzed as a whole group. However, this was only true for those meta-analyses which include less than 10 studies (-0.17% increase in the number of foci per each 10-patient increase in sample-size, P = 0.641), while the regression achieved statistical significance for those meta-analyses including 10 studies or more (0.35% increase in the number of foci per each 10-patient increase in sample-size, P < 0.001, Fig. 7). As shown in Figure 7, there were many metaanalyses with fewer than 10 studies and total sample size <1,000 that reported a substantial number of loci, e.g., six of them reported at least 10 loci, while this occurred in only one meta-analysis with 10 or more studies. The median number of loci was three in meta-analyses with at least 10 studies and five in meta-analyses with fewer than 10 studies.

Number of Reported Foci in Meta-analyses Versus Single Studies Contained in Each Meta-Analysis

The number of foci reported in the meta-analyses was significantly smaller than the number of foci reported in the respective studies contained in each meta-analysis (P < 0.001 with paired test). This difference was also significant when only meta-analyses with 10 or more studies were considered (P < 0.001 with paired test), while it lost the significance for meta-analyses with fewer than 10 studies (P = 0.111 with paired test).

DISCUSSION

This study explored the potential confounding role of biases in VBM studies by assessing whether the number of reported brain abnormalities was positively related to the sample size of the studies, as it would be statistically

		Num	ber of parti	cipants			Ν	umber of fo	oci	
	Min	Q1	Median	Q3	Max	Min	Q1	Median	Q3	Max
(a) All studies	12	33	47	72	545	0	2	6	11	105
Studies of psychiatric disorders	12	34	52	79	425	0	2	5	10	58
Studies of neurological disorders	13	30	41	66	545	0	3	7	13	105
Studies of non-affective psychosis	12	37	62	87	425	0	2	6	12	38
Studies of dementia	13	29	40	63	545	0	3	7	12	105
Studies of neurological diseases other than dementia	16	31	41	66	134	0	2	7	14	48
Studies of anxiety disorders	20	34	39	51	144	0	1	3	7	19
Studies of autism	20	30	33	65	188	0	1	5	9	58
Studies of bipolar disorder	26	48	68	84	132	0	2	6	17	33
Studies of depressive disorders	27	36	60	90	328	0	2	6	11	24
Studies of ADHD	24	31	40	57	128	0	0	4	8	17
Studies published up to 2008	12	30	42	72	425	0	3	7	11	105
Studies published after 2008	13	37	52	72	545	0	2	5	11	48
Studies with up to six authors	12	30	43	69	545	0	3	7	12	33
Studies with more than six authors	13	33	51	74	425	0	2	5	10	105
Studies with less than 32 patients	12	22	26	29	31	0	2	4	9	58
Studies with at least 32 patients	32	41	60	84	545	0	2	6	13	105
Studies with up to 80 patients	12	30	40	59	80	0	2	5	10	58
Studies with magnets up to 1.5T	12	34	52	78	545	0	2	6	10	105
Studies with magnets stronger than 1.5T	16	29	38	59	221	0	2	6	13	58
Studies with slices of 1.5 mm or more	13	35	57	77	425	0	2	6	10	105
Studies with slices inferior to 1.5 mm	12	30	40	70	545	0	2	6	13	58
Studies employing SPM in pre-processing	12	32	45	72	545	0	2	6	12	105
Studies not employing SPM in pre-processing	24	41	63	87	317	0	2	7	10	27
Studies with 8 mm smoothing or less	15	33	48	72	425	0	2	5	12	58
Studies with more than 8 mm smoothing	12	30	45	75	545	0	2	6	11	105
Studies employing SPM in statistics	12	32	45	72	545	0	2	6	12	105
Studies not employing SPM in statistics	24	37	61	83	317	0	2	7	10	27
Studies thresholding at $P < 0.001$ uncorrected	15	30	39	56	425	0	4	7	14	48
Studies thresholding at $P < 0.05$ corrected	12	33	49	72	382	0	2	5	10	105
Studies thresholding at $P < 0.05$ FDR-corrected	16	36	50	64	188	0	2	6	12	58
Studies thresholding at $P < 0.05$ FWE-corrected	13	36	59	90	382	0	2	4	8	105
Studies not employing SVC	12	32	47	71	545		2	6	12	105
Studies employing SVC	20	40	71	123	317		2	3	7	27
(b) All meta-analyses	149	322	534	1042	4087	0	2	3	5	24
Meta-analyses with less than 10 studies	149	259	343	446	952	0	2	5	7	24
Meta-analyses with at least 10 studies	483	873	1247	1652	4087	0	1	3	4	23

TABLE II. Number of participants and reported foci in the VBM studies (a) and meta-analyses (b) included in the present study

expected given that studies with larger sample sizes have more power to detect abnormalities. Overall, we found a weak correlation between sample size and number of reported loci, corresponding to an increase of only 2% per 10 additional patients. This is far less than what would be expected based on power considerations. Thus, it suggests that reporting biases may be inflating the number of discovered reported loci in small studies. Evaluation of a large number of moderator variables suggested similar findings in a wide array of study, disease, technical and other characteristics, although there were hints that the statistical threshold employed and publication year had a modulating effect. Finally, we found that for whole-brain

voxel-based meta-analyses including less than 10 studies, there was no association between sample size and number of loci, which is again suggestive of potential reporting biases. This pattern was not seen in meta-analyses with more than 10 studies, which generally reported few loci (median = 3). The number of loci reported in metaanalyses, especially large ones, was significantly smaller than the number of loci reported in single studies, also corroborating that the literature of single studies may often present inflated numbers of discoveries.

Overall, the strength of the evidence that we found for reporting biases in VBM studies may be weaker than previous findings in non-VBM (i.e., ROI) structural neuroimaging

	Number of studies	Zero-inflated Poisson regression		Meta-analytic Poisson regression ^a		Pearson correlation		Spearman correlation		Meta-analytic correlation ^a	
		Estimate ^b	<i>P</i> -value ^c	Estimate ^b	P value ^c	R	P value ^c	Rho	P value ^c	R	P value ^c
(a) All studies	324	1.935%	< 0.001	2.121%	< 0.001	0.148	0.004	0.139	0.006	0.110	0.005
Studies of psychiatric disorders	215	2.420%	< 0.001	2.165%	< 0.001	0.205	0.001	0.115	0.047	0.107	0.012
Studies of neurological disorders	109	1.458%	< 0.001	1.888%	< 0.001	0.111	0.126	0.246	0.005	0.126	0.113
Studies of non-affective psychosis	98	3.154%	< 0.001	3.319%	< 0.001	0.405	< 0.001	0.284	0.002	0.339	< 0.001
Studies of dementia	58	1.076%	0.004	1.749%	< 0.001	0.089	0.253	0.305	0.010	0.122	0.174
Studies of neurological diseases	51	8.341%	< 0.001	4.191%	0.025	0.227	0.054	0.194	0.087	0.133	0.223
other than dementia											
Studies of anxiety disorders	29	7.376%	< 0.001	7.220%	< 0.001	0.244	0.101	0.227	0.118	0.330	0.003
Studies of autism	27	-9.535%	0.994	-11.034%	>0.999	-0.159	0.785	-0.061	0.620	-0.187	0.928
Studies of bipolar disorder	24	-8.088%	0.999	-10.036%	>0.999	-0.276	0.904	-0.274	0.902	-0.305	0.987
Studies of depressive disorders	23	-2.563%	0.987	-1.634%	>0.999	-0.109	0.690	-0.127	0.718	-0.151	0.918
Studies of ADHD	14	1.975%	0.413	-17.923%	>0.999	-0.382	0.911	-0.408	0.926	-0.408	0.949
Studies published up to 2008	202	2.939%	< 0.001			0.217	0.001	0.179	0.005		
Studies published after 2008	122	0.225%	0.313			0.041	0.326	0.144	0.056		
Studies up to six authors	108	0.615%	0.089			0.066	0.249	0.085	0.191		
Studies with more than six authors	214	2.592%	< 0.001			0.175	0.005	0.161	0.009		
Studies with less than 32 patients	75	52.494%	< 0.001			0.222	0.028	0.282	0.007		
Studies with at least 32 patients	249	1.749%	< 0.001			0.146	0.011	0.113	0.037		
Studies with up to 80 patients	257	5.103%	< 0.001			0.078	0.106	0.110	0.039		
Studies with magnets up to 1.5T	257	2.038%	< 0.001			0.158	0.005	0.114	0.034		
Studies with magnets stronger than 1 5T	60	1 266%	0.103			0.112	0.197	0.233	0.037		
Studies with slices of 15 mm or more	161	2 935%	< 0.001			0.207	0.004	0.175	0.007		
Studies with slices inferior to 15 mm	151	0.850%	0.010			0.074	0.183	0.083	0.0156		
Studies employing SPM in pre-processing	282	1.639%	< 0.010			0.074	0.105	0.000	0.100		
Studies not employing SPM in pre-processing	29	4.943%	<0.001			0.131	0.002	0.151	0.091		
Studies with 8 mm smoothing or less	147	1.746%	< 0.001			0.102	0.110	0.055	0.256		
Studies with more than 8 mm smoothing	152	1.865%	< 0.001			0.161	0.024	0.189	0.010		
Studies employing SPM in statistics	281	1.622%	< 0.001			0.130	0.015	0.150	0.006		
Studies not employing SPM in statistics	30	5.142%	< 0.001			0.529	0.001	0.283	0.065		
Studies thresholding at $P < 0.001$ uncorrected	67	1.270%	0.017			0.129	0.149	0.242	0.024		
Studies thresholding at $P < 0.05$ corrected	182	2.464%	< 0.001			0.150	0.022	0.078	0.147		
Studies thresholding at $P < 0.05$ FDR-corrected	60	-2.760%	0.923			-0.135	0.847	-0.115	0.808		
Studies thresholding at $P < 0.05$ FWE-corrected	49	2.253%	< 0.001			0.204	0.080	0.382	0.003		
Studies not employing SVC	296	1.877%	< 0.001			0.145	0.072	0.165	0.002		
Studies employing SVC	26	5.693%	< 0.001			0.479	0.007	-0.130	0.263		

TABLE III. Relationship between sample size and number of reported foci in subgroups defined by different mod	ler-
ator factors: (a) analyses at the level of single studies and (b) analyses at the level of VBM meta-analyses	

		Poisson regression			orrelation	Spearman correlation		
	Number of studies	Estimate ^b	P value ^c	R	P value ^c	Rho	P value ^c	
(b) All meta-analyses	47	0.0148%	0.423	0.012	0.469	-0.065	0.668	
Meta-analyses with <10 studies	25	-0.1653%	0.641	-0.031	0.558	0.149	0.238	
Meta-analyses with 10 studies or more	22	0.3498%	< 0.001	0.348	0.056	0.330	0.067	

^aMeta-analytical combination of the Poisson regressions or the (Fisher-transformed) correlations separately estimated per each published meta-analysis.

^bIncrease in the number of reported foci per each increase of 10 patients.

^c*P* values were obtained from one-tailed tests.



Figure 4.

Relationship between sample size and identified number of foci with abnormalities.

studies, where an excess significance bias was more clearly detected [Ioannidis, 2011]. However, the ROI assessment evaluated the number of observed versus expected significant results in each study and in multiple studies, while this was not possible to do for VBM studies given the nature of the data. Second, automated methods such as VBM tend to be less biased by the researcher's influence; in contrast, a researcher could perform several exploratory ROI analyses and report results for only those ROIs that yielded significant results [Ioannidis, 2011; Radua and Mataix-Cols, 2012]. Third, the manual tracing of ROIs, as compared with VBM methods, can introduce significant heterogeneity in the anatomical definition of the brain areas investigated across studies and thus affect the significance of the results reported, hampering publication biases. Fourth, we found that the median sample size of the individual VBM studies retrieved was of 47, which is larger than the typical sample size of previously analyzed ROI studies [Ioannidis, 2011]. Some authors have even proposed optimal sample sizes for individual VBM studies of 16-32 subjects per group [Friston, 2012], suggesting that between-subjects comparison studies of n < 32 are too small even by liberal estimates. Still the fact that the number of loci reported in single VBM studies is smaller than what eventually gets validated in large meta-analyses suggests that reporting or other biases may sometimes be substantial in some VBM studies.

We explored several potential factors that may be influencing and modulating reporting biases in VBM literature such as publication year, type of condition investigated, statistical threshold employed and other methodological characteristics of the analysis method. A similar pattern of weak or null correlations was seen in several analyses according to different moderator variables although we found some hints that statistical threshold employed and publication year had some modulating effect. There was no difference in the relationship between identified foci and sample size according to type of clinical conditions. Similarly, no differences in the relationship between number of foci and sample size were detected when VBM psychiatric literature was compared with the VBM neurological literature. Factors other than publication biases may account for the lack of clinical applications of psychiatric neuroimaging (e.g., heterogeneity of psychiatric diagnoses or differences in the psychopathological characteristics across samples) [Borgwardt et al., 2012]. Sample size, magnet field, slices thickness, type of analysis package, type of smoothing kernel, use of SVC did not affect the results.

Conversely, the foci-sample relationship was positive and statistically significant in studies employing an FWE correction, negative and non-significant in studies applying an FDR correction, even if the increase of foci related to sample size should be higher in studies applying such correction (Fig. 1). Furthermore, there was a statistically significant difference between subgroups. The reasons for the existence of potential bias in studies using an FDR are again speculative. It should be noted that sample size range appeared to be smaller for VBM studies which employed FDR correction (see Fig. 6); it is therefore possible that the absence of a significant relationship for studies which used FDR but not for those which used few correction could simply be explained by differences in power.



Figure 5.

Relationship between number of authors and number of identified foci.



Figure 6.

Relationship between sample size and number of identified foci in studies using FDR correction for multiple comparisons and those using FWE correction for multiple comparisons. Difference in regression slope P = 0.005.

Alternatively, the absence of a relationship between sample size and foci in studies applying an FDR correction could be related to some mis-use of FDR in neuroimaging [Chumbley and Friston, 2009].

In addition, found an effect of the number of authors, with significant correlation between sample size and number of foci for VBM studies with more than six authors and no correlation for studies with up to six authors (statistically significant between-subgroups differences, Fig. 5). Strikingly, we replicated the similar relationship previously reported by Sayo et al. (2011), who found that studies with less coauthors reported larger ventricular-brain

ratio abnormalities in patients with schizophrenia. They suggested that larger research groups may be more conservative or exacting in their research methodology. Similarly, we also found a differential effect for publication year, with significant correlation between sample size and number of foci for VBM studies published up to 2008 and no correlation for studies published after 2008 (statistically significant between-subgroups differences). The reasons for this observation are highly speculative and it could be a chance finding, given the number of modulator variables assessed. It could be, for instance, that as far as the structural abnormalities in many disorders have been more or less established in previous studies, only studies finding such abnormalities are published. Alternatively, newer studies use advanced VBM algorithms (i.e., DARTEL [Ashburner, 2007b], introduced shortly before 2008) [Ashburner, 2007a] which could enable them to detect most of the abnormalities with even relatively small sample sizes. However, this seems unlikely to be the case given that the number of foci reported in these studies is indeed lower than in older studies (9-74% decrease depending on the sample size). The causes for this observation are highly speculative. On the one hand, in recent years investigators may have conservatively thresholded the analyses when the results appeared in brain regions that were unexpected based on the results of previous studies. On the other hand, some of the new VBM algorithms that have been introduced based on theoretical grounds lack formal empirical validations and may have had a detrimental impact on the sensitivity of the analyses. A third possibility is that these new VBM algorithms have resulted in fewer false-positives compared to standard VBM, for instance by improving the spatial registration of the images or minimizing the impact of non-normality [Salmond et al., 2002; Viviani et al., 2007]. Because the causes for the lower number of significant foci after 2008 are speculative, the implications of this observation for the minimal appropriate N per group are also unclear.

Finally, we tested the sample size/number of foci correlation hypothesis at meta-analytical level (Fig. 7). We found that the relationship was absent when metaanalyses with less than 10 studies were included in a Poisson regression. Small meta-analyses report more foci than larger ones. This finding may be useful to guide editors, reviewers and authors to improve the reliability of voxelbased meta-analyses by either setting the bar for the number of required studies included in meta-analyses at $k \ge 10$ or ensuring that high-quality null findings in metaanalyses of conditions with k < 10 available published singleton studies are available after systemic literature review, and ideally, also access to registries of data, since it is notoriously difficult to unearth unpublished unregistered data. The fact that meta-analyses with many studies validate few foci (median = 3) is also suggestive that the larger numbers of foci reported in small studies and small meta-analyses may be inflated by several falsepositives.





Relationship between sample size and number of identified foci in all meta-analyses (above), meta-analyses with at least 10 studies (bottom left) and meta-analyses with less than 10 studies (bottom right).

Some caveats should be discussed about our study. First, we cannot rule out the possibility that in some cases large studies and even large meta-analyses may suffer from reporting and/or other biases that inflate the number of discovered loci. Conversely, some small studies may be more meticulous and thus optimize the yield of discoveries, despite their limited sample size. However, it is unlikely that there would be a systematic error in favor of small studies being better than larger studies in this regard. Our analysis focuses on the large picture including many hundreds of studies. Second, the total number of genuine loci to be dis-

covered in each disease and condition is unknown and power calculations require making assumptions about how many of such abnormalities would be detected. Most likely, the number and magnitude of abnormalities differs substantially across different diseases and conditions. Thus, again, our approach offers an aggregate view of the big picture and inferences may not be possible to extrapolate to each of the topics that we analyzed. Even if reporting biases are present in the field-at-large, this does not mean that all sub-fields and each topic are equally affected. Third, there is preliminary evidence that VBM studies with a smaller sample size may be more susceptible to false positive rates than those with a larger sample size; this is due to the impact of nonnormality of the data [Salmond et al., 2002; Viviani et al., 2007] which is critically dependent on sample size [Scarpazza et al., in press]. Thus we cannot exclude the possibility that our results reflect differences in false positive rates as a function of sample size rather than reporting biases.

CONCLUSIONS

Acknowledging these caveats our analysis offers some evidence about the relationship between sample size and number of discovered loci that can be used in designing the future research agenda for VBM studies and in interpreting the results of single studies and meta-analyses thereof in this discipline.

REFERENCES

- Ashburner J (2007a): A fast diffemorphic image registration algorithm. Neuroimage 38:95–113.
- Ashburner J (2007b): A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113.
- Ashburner J, Friston KJ (2000): Voxel-based morphometry-the methods. Neuroimage 11:805–821.
- Belsley DA, Kuh K, Welsch RE (1980): Regression diagnostics: Identifying influential data and sources of collinearity. New York: John Wiley & Sons.
- Borgwardt S, Fusar-Poli P (2012): Third-generation neuroimaging in early schizophrenia: Translating research evidence into clinical utility. Br J Psychiatry 200:270–272.
- Borgwardt S, Radua J, Mechelli A, Fusar-Poli P (2012): Why are psychiatric imaging methods clinically unreliable? Conclusions and practical guidelines for authors, editors and reviewers. Behav Brain Funct 8:46.
- Chumbley JR, Friston KJ (2009): False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage 44:62–70.
- David SP, Ware JJ, Chu IM, Loftus PD, Fusar-Poli P, Radua J, Munafo MR, Ioannidis JP (2013): Potential reporting bias in FMRI studies of the brain. PLoS One 8:e70104. doi: 10.1371/ journal.pone.0070104.
- Friston K (2012): Ten ironic rules for non-statistical reviewers. Neuroimage 61:1300–1310.
- Ioannidis JP (2011): Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 68:773–780.

- Laird AR, Fox PM, Price CJ, Glahn DC, Uecker AM, Lancaster JL, Turkeltaub PE, Kochunov P, Fox PT (2005): ALE meta-analysis: Controlling the false discovery rate and performing statistical contrasts. Hum Brain Mapp 25:155–164.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009): The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6: e1000100.
- Peters BD, Szeszko PR, Radua J, Ikuta T, Gruner P, Derosse P, Zhang JP, Giorgio A, Qiu D, Tapert SF, Brauer J, Asato MR, Khong PL, James AC, Gallego JA, Malhotra AK (2012): White matter development in adolescence: Diffusion tensor imaging and meta-analytic results. Schizophr Bull, Nov 38(6):1308–17. doi: 10.1093/schbul/sbs054. Epub 2012 Apr 12.
- R_Development_Core_Team (2011): R: A language and environment for statistical computing. In: Computing RFfS, editor. Vienna: R_Development_Core_Team.
- Radua J, Mataix-Cols D (2009): Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br J Psychiatry 195:393–402.
- Radua J, Mataix-Cols D (2012): Meta-analytic methods for neuroimaging data explained. Biol Mood Anxiety Disord 2:6.
- Radua J, van den Heuvel OA, Surguladze S, Mataix-Cols D (2010a): Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Arch Gen Psychiatry 67:701–711.
- Radua J, Via E, Catani M, Mataix-Cols D (2010b): Voxel-based meta-analysis of regional white matter volume differences in Autism Spectrum Disorder vs. healthy controls. Psychol Med 41:1539–1550.
- Radua J, Mataix-Cols D, Phillips ML, El-Hage W, Kronhaus DM, Cardoner N, Surguladze S (2012a): A new meta-analytic method for neuroimaging studies that combines reported peak

coordinates and statistical parametric maps. Eur Psychiatry 27: 605–611.

- Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (2012b): Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev 36:2325–2333.
- Radua J, Canales-Rodriguez EJ, Pomarol-Clotet E, Salvador R (2013): Validity of modulation and optimal settings for advanced voxel-based morphometry. Neuroimage, in Press. doi: 10.1016/j.neuroimage.2013.07.084.
- Rothstein HR, Sutton A, Borenstein M (2005): Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustment. Chichester, UK: Wiley.
- Salmond CH, Ashburner J, Vargha-Khadem F, Connelly A, Gadian DG, Friston KJ (2002): Distributional assumptions in voxel-based morphometry. Neuroimage 17:1027–1030.
- Sayo A, Jennings RG, Van Horn JD (2011): Study factors influencing ventricular enlargement in schizophrenia: A 20 year follow-up meta-analysis. Neuroimage 59:154–167.
- Scarpazza C, Sartori G, De Simone M, Mechelli A: When the single matters more than the group: Very high false positive rates in single case voxel based morphometry. Neuroimage, 2013 Apr 15;70:175–88. doi: 10.1016/j.neuroimage.2012.12.045. Epub 2013 Jan 2.
- Simon Jackman (2012). pscl: Classes and Methods for R Developed in the Political Science Computational Laboratory, Stanford University. Department of Political Science, Stanford University. Stanford, California. R package version 1.04.4. http:// pscl.stanford.edu/.
- Viviani R, Beschoner P, Ehrhard K, Schmitz B, Thone J (2007): Nonnormality and transformations of random fields, with an application to voxel-based morphometry. Neuroimage 35:121–130.
- Zeleis A, Kleiber C, Jackman S (2008): Regression models for count data in R. J Stat Software 27.